NO patients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug
Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within  week prior to study registration (subjects already receiving erythropoietin on a chronic basis for >=  days are eligible)
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of the study drugs.
Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within  week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >=  weeks are eligible)
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug.
Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within  week before administration of the first dose of study drug (participants already receiving erythropoietin on a chronic basis for >= weeks are eligible).
Patients receiving corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug
Patients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug
Patients receiving systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers or low-dose hormone replacement therapy as defined no greater than  mg of prednisone daily) within  week before administration of the first dose of study drug
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug
Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within  week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >=  weeks are eligible)
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug
Initiation of treatment with hematopoietic growth factors, transfusions of blood and blood products, or systemic corticosteroids (either intravenous [IV] or oral steroids, excluding inhalers) within  week before administration of the first dose of study drug (patients already receiving erythropoietin on a chronic basis for >=  weeks are eligible)
Patients receiving systemic corticosteroids (either IV or oral steroids, excluding inhalers or low-dose hormone replacement therapy) within  week before administration of the first dose of study drug